• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物的依从率阈值具有药物特异性。

The Adherence Rate Threshold is Drug Specific.

机构信息

ScribCo, Effort, PA, USA.

University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA.

出版信息

Drugs R D. 2017 Dec;17(4):645-653. doi: 10.1007/s40268-017-0216-6.

DOI:10.1007/s40268-017-0216-6
PMID:29076037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5694429/
Abstract

INTRODUCTION

Patient adherence to a medication regimen is usually expressed as an adherence rate, defined as the proportion of prescribed doses actually taken. An adherence rate threshold, above which the therapeutic effect is maintained, is typically assigned an arbitrary value, commonly 0.8.

OBJECTIVE

Here, we determined the value of the adherence rate threshold objectively in different drugs of the same class, using statins as an example.

METHODS

We used pharmacokinetic/pharmacodynamic (PK/PD) modeling to predict serum levels of low-density lipoprotein cholesterol (LDL-C) in patients taking simvastatin 20 mg or atorvastatin 5 mg once daily for 30 days. LDL-C reduction was modeled for adherence rates of 1.0, 0.8, 0.6, 0.4, and 0.2. The results were expressed as the percentage of time spent at the LDL-C goal (< 70 mg/dL). The adherence rate threshold was defined as the minimum adherence rate that resulted in the same amount of time at goal as perfect adherence (i.e., a rate of 1.0).

RESULTS

For simvastatin, an adherence rate of 0.8 resulted in a significant decrease in time at the LDL-C goal compared to perfect adherence (54.8% versus 85.1%; P < 0.001), and rates < 0.8 resulted in progressively less time at goal. For atorvastatin, the rates of 0.8 and 0.6 resulted in essentially the same amount of time at goal as perfect adherence (87.8% and 87.7%, respectively, versus 88.1%; P > 0.05 for both), with less time at goal only occurring at rates ≤ 0.4 (P < 0.001). Thus, the adherence rate thresholds are > 0.8 for simvastatin and between 0.4 and 0.6 for atorvastatin.

CONCLUSION

These results indicate that a value of 0.8 cannot be applied universally.

摘要

简介

患者对药物治疗方案的依从性通常以依从率表示,定义为实际服用的规定剂量比例。通常会为维持治疗效果的依从率阈值指定一个任意值,通常为 0.8。

目的

本研究以他汀类药物为例,旨在客观确定同一类药物中不同药物的依从率阈值值。

方法

我们使用药代动力学/药效学(PK/PD)模型预测服用辛伐他汀 20mg 或阿托伐他汀 5mg 每天一次的患者在 30 天内的低密度脂蛋白胆固醇(LDL-C)的血清水平。对于依从率为 1.0、0.8、0.6、0.4 和 0.2 的患者,模拟 LDL-C 降低情况。结果表示 LDL-C 目标(<70mg/dL)的达标时间百分比。依从率阈值定义为与完全依从(即依从率为 1.0)达到相同目标时间的最低依从率。

结果

对于辛伐他汀,与完全依从相比,依从率为 0.8 时 LDL-C 目标的达标时间显著减少(54.8% 比 85.1%;P<0.001),而依从率<0.8 时目标达标时间逐渐减少。对于阿托伐他汀,0.8 和 0.6 的依从率与完全依从达到的目标时间基本相同(分别为 87.8%和 87.7%,与 88.1%相比,P>0.05),只有在依从率≤0.4 时目标达标时间才会减少(P<0.001)。因此,辛伐他汀的依从率阈值>0.8,阿托伐他汀的阈值在 0.4 和 0.6 之间。

结论

这些结果表明,0.8 的值不能普遍适用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/c4800c3f3dc1/40268_2017_216_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/c553b51ac87d/40268_2017_216_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/9bc3877e2dbd/40268_2017_216_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/31e3c60e4aa4/40268_2017_216_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/c4800c3f3dc1/40268_2017_216_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/c553b51ac87d/40268_2017_216_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/9bc3877e2dbd/40268_2017_216_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/31e3c60e4aa4/40268_2017_216_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bc8/5694429/c4800c3f3dc1/40268_2017_216_Fig4_HTML.jpg

相似文献

1
The Adherence Rate Threshold is Drug Specific.药物的依从率阈值具有药物特异性。
Drugs R D. 2017 Dec;17(4):645-653. doi: 10.1007/s40268-017-0216-6.
2
Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol.从阿托伐他汀转换为辛伐他汀治疗高心血管风险患者:对低密度脂蛋白胆固醇的影响。
Am J Ther. 2010 Mar-Apr;17(2):167-75. doi: 10.1097/MJT.0b013e3181b442b9.
3
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.使用间接效应模型描述他汀类药物对高胆固醇血症患者的低密度脂蛋白胆固醇降低作用。
Fundam Clin Pharmacol. 2006 Jun;20(3):321-30. doi: 10.1111/j.1472-8206.2006.00404.x.
4
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.他汀类药物治疗胆固醇水平达标:临床管理指南建议与实际临床实践管理的比较。
Pharmacotherapy. 2012 Jul;32(7):631-41. doi: 10.1002/j.1875-9114.2011.01086.x.
5
Adherence to statins and LDL-cholesterol goal attainment.他汀类药物的依从性与低密度脂蛋白胆固醇目标达成情况。
Am J Manag Care. 2014 Apr 1;20(4):e105-12.
6
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.在常规临床实践中,与其他他汀类药物相比,瑞舒伐他汀治疗的老年患者的低密度脂蛋白胆固醇(LDL-C)水平及LDL-C达标情况。
Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002.
7
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.在继续使用阿托伐他汀或转换为等效或非等效剂量辛伐他汀的患者中 LDL-C 目标的达成:临床实践中的回顾性匹配队列研究。
Postgrad Med. 2010 Mar;122(2):16-24. doi: 10.3810/pgm.2010.03.2118.
8
Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.初级保健中他汀类药物使用者 LDL-C 目标达标情况和自我报告药物依从性的前瞻性分析。
Clin Ther. 2011 Sep;33(9):1180-9. doi: 10.1016/j.clinthera.2011.07.007. Epub 2011 Aug 12.
9
Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.老年患者新开始使用阿托伐他汀或辛伐他汀后的药物使用模式及心血管结局
Am J Geriatr Pharmacother. 2011 Dec;9(6):471-82. doi: 10.1016/j.amjopharm.2011.09.004. Epub 2011 Oct 21.
10
A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia.用于预测原发性高脂血症患者低密度脂蛋白胆固醇降低的辛伐他汀群体药代动力学-药效学模型。
Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):156-63. doi: 10.1111/j.1742-7843.2011.00700.x. Epub 2011 May 14.

引用本文的文献

1
Absorbing Markov chain model of PrEP drug adherence to estimate adherence decay rate and probability distribution in clinical trials.用于估计临床试验中暴露前预防药物依从性衰减率和概率分布的吸收马尔可夫链模型。
J Theor Biol. 2025 May 7;604:112086. doi: 10.1016/j.jtbi.2025.112086. Epub 2025 Mar 13.
2
Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data.比利时慢性髓性白血病患者的伊马替尼依从性和持续性:来自真实世界数据的证据
Patient Prefer Adherence. 2024 Sep 25;18:1991-2006. doi: 10.2147/PPA.S472478. eCollection 2024.
3
Association Between Oral Anticoagulant Adherence and Serious Clinical Outcomes in Patients With Atrial Fibrillation: A Long-Term Retrospective Cohort Study.

本文引用的文献

1
Relationship Between Adherence Rate Threshold and Drug 'Forgiveness'.药物“宽容度”与服药依从性阈值的关系
Clin Pharmacokinet. 2017 Dec;56(12):1435-1440. doi: 10.1007/s40262-017-0552-2.
2
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南。
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
3
Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis.抗逆转录病毒治疗的依从性与病毒学失败:一项荟萃分析。
口服抗凝药物治疗依从性与房颤患者严重临床结局的相关性:一项长期回顾性队列研究。
J Am Heart Assoc. 2024 Sep 17;13(18):e035639. doi: 10.1161/JAHA.124.035639. Epub 2024 Sep 9.
4
Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.利用数学模型分析镰状细胞病患者羟基脲治疗的不依从性。
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):748-757. doi: 10.1002/psp4.12945. Epub 2023 May 16.
5
Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross-Sectional Analysis of Centralized Procedures in the European Union 2010-2020.在支持新药批准的注册试验中,药物依从性测量方法:2010-2020 年欧盟集中程序的横断面分析。
Clin Pharmacol Ther. 2022 Nov;112(5):1051-1060. doi: 10.1002/cpt.2709. Epub 2022 Jul 30.
6
Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study.漏服剂量对甲氨蝶呤治疗类风湿关节炎疗效的影响:一项药代动力学建模研究
Open Access Rheumatol. 2021 Sep 14;13:267-274. doi: 10.2147/OARRR.S329178. eCollection 2021.
7
Patterns of non-adherence to oral antiretroviral medication: frequencies of consecutively missed doses.口服抗逆转录病毒药物的不依从模式:连续漏服剂量的频率。
Patient Prefer Adherence. 2019 Mar 11;13:389-394. doi: 10.2147/PPA.S192153. eCollection 2019.
8
Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain.基于处方或配药信息估算依从性:对阈值和结果的影响。西班牙口服抗凝剂治疗心房颤动患者的一项真实世界研究。
Front Pharmacol. 2018 Dec 3;9:1353. doi: 10.3389/fphar.2018.01353. eCollection 2018.
9
Acceptable medication non-adherence: A crowdsourcing study among French physicians for commonly prescribed medications.可接受的药物不依从:一项针对法国医生的常见处方药物的众包研究。
PLoS One. 2018 Dec 13;13(12):e0209023. doi: 10.1371/journal.pone.0209023. eCollection 2018.
10
A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes.对依赖临床结果的药物依从性阈值的系统评价。
Front Pharmacol. 2018 Nov 20;9:1290. doi: 10.3389/fphar.2018.01290. eCollection 2018.
Medicine (Baltimore). 2016 Apr;95(15):e3361. doi: 10.1097/MD.0000000000003361.
4
Defining medication adherence in individual patients.定义个体患者的药物依从性。
Patient Prefer Adherence. 2015 Jul 1;9:893-7. doi: 10.2147/PPA.S86249. eCollection 2015.
5
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy.高效抗逆转录病毒治疗时代的依从性与HIV RNA抑制
J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):493-8. doi: 10.1097/QAI.0000000000000643.
6
Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia.在血脂异常初治患者中,隔日服用与每日一次服用阿托伐他汀用于冠心病一级预防的比较
J Clin Diagn Res. 2014 Mar;8(3):27-31. doi: 10.7860/JCDR/2014/7359.4096. Epub 2014 Mar 15.
7
Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records.基于电子病历的他汀类药物及联合用药降低低密度脂蛋白胆固醇作用的群体药效学分析
Br J Clin Pharmacol. 2014 Oct;78(4):824-35. doi: 10.1111/bcp.12405.
8
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013年美国心脏病学会/美国心脏协会成人降低动脉粥样硬化性心血管风险的血胆固醇治疗指南:美国心脏病学会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
9
Alternate-day dosing with statins.隔日给予他汀类药物治疗。
Am J Med. 2013 Feb;126(2):99-104. doi: 10.1016/j.amjmed.2012.08.007.
10
Revisiting the medication possession ratio threshold for adherence in lipid management.重新审视血脂管理中药物依从性的用药维持率阈值。
Curr Med Res Opin. 2013 Mar;29(3):175-80. doi: 10.1185/03007995.2013.766164. Epub 2013 Feb 1.